CClinicalTrials.gg
CompletedNCT02636166Updated Dec 21, 2015

Project-0027. Lay User Usage Study

An interventional study of Clearblue Investigational Pregnancy test and Professional pregnancy test in Pregnancy, sponsored by SPD Development Company Limited. Completed at 1 site in United Kingdom. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-21.

Sponsored by SPD Development Company Limited · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
943
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

Study volunteers will be required to conduct a home pregnancy test (HPT) at the trial centre and provide a sample of urine from the same void for further testing.

Volunteers will then complete a product usage questionnaire and leaflet comprehension questionnaire at site.

Follow-up information will be required from all volunteers as both additional urine sample(s) and pregnancy information to establish true pregnancy status at the study visit.

Read the detailed description

Eligible volunteers will be recruited into the study and provide informed consent. Volunteers will then test their urine sample with the investigational HPT according to the device Instructions for use and record their result onto the results sheet. A sample of urine from the same void will be obtained for further testing by the study technicians.

The technician will then test the volunteer's sample with a second investigational HPT, a professional use pregnancy test and a Clearblue Digital HPT, the results of which will be used to provide the volunteer with her pregnancy test result. During technician testing, the volunteer will complete the device usability and leaflet comprehension questionnaires.

At the end of the study visit, all volunteers will be provided with materials to allow follow-up for the determination of pregnancy status.

The majority of volunteers will be requested to provide one additional urine sample, collected 2 days after the study visit. If early pregnancy is suspected the volunteer will be requested to provide an additional 7 daily urine samples following the study visit. All volunteers will be required to provide details of pregnancy status (documented menses or pregnancy confirmation by health care professional) after the study visit.

True pregnancy status will be determined by laboratory tests and clinical information. The study will continue until a minimum of 300 pregnant and 300 not pregnant volunteers have completed the study.

02

Conditions studied

  • Pregnancy

Keywords

  • Pregnancy
03

In context

Lead sponsor

SPD Development Company Limited is the lead sponsor of 30 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Female
  • Aged 18 or over
  • Willing to conduct a personal pregnancy test and reveal their pregnancy status
  • Willing to give informed consent

Exclusion criteria

Exclusion Criteria:

  • Currently or previously employed by SPD Development Company Ltd. (SPD), Alere, Unipath, Procter and Gamble (P\&G), or affiliates.
  • Has an immediate relative* currently or previously employed by SPD, Alere, Unipath or P\&G or affiliates
  • Previously used the investigational HPT within the last six months
  • Healthcare professionals (HCP's) with professional experience either using lateral flow based devices or conducting near patient testing
  • Confirmed to be pregnant by a healthcare professional and beyond the first trimester
  • Taken a hormonal preparation containing human chorionic gonadotropin (hCG) in the last month, e.g. Pregnyl®
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
943 participants (actual)

Study arms

  • Other
    Pregnancy test

    Clearblue investigational Pregnancy test Clearblue Marketed pregnancy test Professional pregnancy test

    Other: Clearblue Investigational Pregnancy test · Other: Professional pregnancy test · Other: Clearblue Marketed Pregnancy test

Interventions

  • OtherClearblue Investigational Pregnancy test

    Clearblue Investigational Pregnancy test

  • OtherProfessional pregnancy test

    Alere Professional use pregnancy test

  • OtherClearblue Marketed Pregnancy test

    Clearblue Marketed Pregnancy test

06

What researchers measure

Primary outcomes

  1. Number of participants recording the correct pregnancy test result when testing their own urine sample with the investigational HPT referenced to confirmed pregnancy status

    The accuracy of the investigational HPT in volunteer hands compared to pregnancy status

    Time frame: 3 months

Secondary outcomes

  1. Number of participants recording the same pregnancy test result as a laboratory technician when testing their own urine sample with the investigational HPT.

    The agreement between volunteer and technician results using the investigational HPT

    Time frame: 3 months

  2. Number of participants recording a false positive or false negative pregnancy test result when testing their own urine sample with the investigational HPT referenced to confirmed pregnancy status.

    The estimated sensitivity and specificity of the investigational HPT

    Time frame: 3 months

  3. Calculation of the level of certainty a user can have if the device gives a pregnant (positive predictive value (PPV)) or not pregnant result (Negative predictive value(NPV)).

    The estimated NPV and PPV of the investigational HPT

    Time frame: 3 months

  4. Number of participants correctly answering questions about the product when referencing the instructions for use (IFU) leaflet.

    Volunteer leaflet comprehension of the IFU

    Time frame: 3 months

  5. Participants opinion on using the product.

    Volunteer usability of the IFU

    Time frame: 3 months

07

Study locations

1 site
  • Illingworth Research Ltd
    Macclesfield, Chester SK11 7QJ, United Kingdom
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 21, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02636166
Lead sponsor
SPD Development Company Limited
Collaborators
Illingworth Research Ltd
Responsible party
Sponsor
First posted
Dec 21, 2015
Start date
Jul 2015
Primary completion
Nov 2015
Completion
Dec 2015
Last update
Dec 21, 2015

Study contacts

Juliet Hulse
principal investigator · Illingworth Research Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion